Professor Minghao Zheng has made significant contributions in the understanding of fundamental bone biology and translating research into industry and commercialisation.

After studying medicine at Shantou University and Sun Yat-sen University of Medical Sciences in China, Professor Zheng came to The University of Western Australia in 1989, receiving a PhD in 1993 and Doctor of Medicine in 2000. He is fellow of the Royal College of Pathologists, UK and the Royal College of Pathologists of Australasia. He is a member of Faculty 1000 Prime and Associate Editor of Stem Cell Research and Therapy.

Professor Zheng holds the position of Winthrop Professor of Orthopaedic Research at UWA. 

Professor Zheng's career has centred on bone and joint research and regenerative medicine. He pioneered the development of collagen scaffolds and cell therapy to treat cartilage, tendon and ligament injury, and is a global leader in regeneration of tendon and cartilage using a patient’s own stem cells. He developed the Matrix-induced Autologous Chondrocyte Implantation (MACI) cartilage repair protocol and Autologous Tenocyte Therapy (ATT) for tendon repair. His work on Giant Cell Tumour of bone is used by the World Health Organisation for the official classification of bone tumours. He has published over 250 papers and holds eight patented grants in Australia, USA, Japan, Singapore, Europe and China.

In addition to academic and university leadership roles, Professor Zheng is Co-Founder and Consultant Chief Scientific Officer of Orthocell Limited (ASX:OCC), a biomedical healthcare company.